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Abstract
Background: Involvement of MMP-9, uPAR and cathepsin B in adhesion, migration, invasion, proliferation, metastasis and
tumor growth has been well established. In the present study, MMP-9, uPAR and cathepsin B genes were downregulated in
glioma xenograft cells using shRNA plasmid constructs and we evaluated the involvement of integrins and changes in their
adhesion, migration and invasive potential.
Methodology/Principal Findings: MMP-9, uPAR and cathepsin B single shRNA plasmid constructs were used to
downregulate these molecules in xenograft cells. We also used MMP-9/uPAR and MMP-9/cathepsin B bicistronic constructs
to evaluate the cumulative effects. MMP-9, uPAR and cathepsin B downregulation significantly inhibits xenograft cell
adhesion to several extracellular matrix proteins. Treatment with MMP-9, uPAR and cathepsin B shRNA of xenografts led to
the downregulation of several alpha and beta integrins. In all the assays, we noticed more prominent effects with the
bicistronic plasmid constructs when compared to the single plasmid shRNA constructs. FACS analysis demonstrated the
expression of aVb3, a6b1 and a9b1 integrins in xenograft cells. Treatment with bicistronic constructs reduced aVb3, a6b1
and a9b1 integrin expressions in xenograft injected nude mice. Migration and invasion were also inhibited by MMP-9, uPAR
and cathepsin B shRNA treatments as assessed by spheroid migration, wound healing, and Matrigel invasion assays. As
expected, bicistronic constructs further inhibited the adhesion, migration and invasive potential of the xenograft cells as
compared to individual treatments.
Conclusions/Significance: Downregulation of MMP-9, uPAR and cathespin B alone and in combination inhibits adhesion,
migration and invasive potential of glioma xenografts by downregulating integrins and associated signaling molecules.
Considering the existence of integrin inhibitor-resistant cancer cells, our study provides a novel and effective approach to
inhibiting integrins by downregulating MMP-9, uPAR and cathepsin B in the treatment of glioma.
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Introduction
Integrins are a family of adhesion molecules involved in
interactions between the cell and the surrounding extracellular
matrix (ECM). Although the classic role of integrins is to anchor
cells to the ECM, they are known to participate in a variety of
signaling pathways and to play important roles in fetal
development, morphogenesis, cell migration, wound healing, and
malignant transformation [1–6]. The heterodimerization of 19a-
integrin and 8b-integrin subunits is thought to yield 25 integrin ab
heterodimers, which form receptors for an overlapping group of
ECM molecules in almost every cell type [7]. Through interactions
with the ECM, integrins control many cellular processes that occur
in the progression of diseases such as cancer. Integrin signaling
regulates diverse functions in tumor cells, including migration,
invasion, proliferation and survival. In several tumor types, the
expression of particular integrins correlates with increased disease
progression and decreased patient survival [8].
Glioblastoma multiforme (GBM) is a highly malignant neo-
plasm of central nervous system. Strategies to treat infiltrating
gliomas, such as chemotherapy and gene therapy, have remained
largely unsuccessful and the property that makes glioma resistant
to treatment is the tendency of the tumor cells to invade normal
brain tissue [9]. Invasiveness is thus considered to be a major
determinant of the malignant behavior of human gliomas.
Integrins, the family of adhesive receptors promote the invasive-
ness of glioma. The role of integrins in cell migration and invasion
is one of their most studied functions in tumor biology [10,11].
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11583Integrins directly bind components of the ECM and provide the
traction necessary for cell motility and invasion. ECM remodeling
is also controlled by integrins, which regulate the localization and
activity of proteases. Proteases involved in these processes include
serine proteases (the plasminogen activators uPA and tPA), matrix
metalloproteinases (MMPs), and cysteine proteases (cathepsins B,
D, L and H) [12].
GBM cells secrete MMPs and their mRNA and protein levels
are elevated in patient biopsy tissues [13–15]. Significant
correlation between MMP-9 levels and the histological grade of
malignancy has been reported [16]. Furthermore, interactions
between integrins expressed by glioma cells and the ECM and the
activity of MMPs form the basis for glioma cell migration and
invasion [17]. Expression of urokinase-type plasminogen activator
receptor (uPAR) is much more robust in high-grade than in low-
grade human gliomas [18]. Localization of uPAR mRNA in
astrocytoma cells and the endothelial cells within brain tumor
tissue has been reported and the expression of uPAR in the
invading astrocytoma cells appears to have a critical role in the
invasive behavior of glioblastoma [18]. Despite the controversy
surrounding whether uPAR and integrins interact directly, many
studies show that uPAR signaling requires integrin co-receptors.
Furthermore, some non-integrin co-receptors of uPAR cooperate
with integrins in signaling or influence uPAR-integrin interactions
[19,20]. Additionally, uPA-uPAR binding results in the expression
of cathepsin B [21], another important protease involved in ECM
degradation, and significantly higher levels of cathepsin B has been
found in high-grade glioblastomas [22,23].
Taken together, the proteases MMP-9, uPA and Cathepsin B
play critical roles in glioma pathology and have the combined
ability to break down the ECM components. Moreover, the
expression of one protease has a direct or indirect influence on the
expression of other proteases. As such, the net proteolytic, and
therefore invasive, potential of a given tumor cell might depend on
the interplay between many proteolytic enzymes. In this scenario,
targeting only one protease will definitely not result in the expected
therapeutic outcome. Hence, in the present study, we investigated
the effect of downregulating MMP-9, uPAR and ctahepsin B using
both single as well as MMP-9/uPAR and MMP-9/cathepsin B
bicistronic shRNA plasmid constructs on the expression of
integrins and on the migrating and invasive potential of glioma
xenograft cells.
Results
Effect of shRNA constructs on MMP-9, uPAR, and
cathepsin B
Gelatin zymography revealed an inhibition of MMP-9 activity
with all the treatments (Fig. 1A). The activity/expression of one
protease has a direct or indirect influence on the activity/
expression of other proteases. Our results were also in agreement
with this fact and hence we noticed a prominent reduction in
Figure 1. Efficiency of shRNA plasmid constructs and their effect on adhesion of xenografts to various ECM proteins. (A) Activity,
protein and mRNA expressions of MMP-9, uPAR and cathepsin B in 4910 xenograft cells. MMP-9 and uPA activity was determined by gelatin and fibrin
zymography after treatments with scrambled vector (SV-sh), MMP-9 (M-sh), uPAR (U-sh), cathepsin B (C-sh), MMP-9/uPAR (MU-sh) and MMP-9/
cathepsin B (MC-sh) plasmid shRNAs. Western blot analysis showing MMP-9, uPAR and cathepsin B protein expression levels were reduced after M-sh,
U-sh, C-sh, MU-sh and MC-sh treatments. n=3. RT-PCR of 4910 cells transfected with SV-sh, M-sh, U-sh, C-sh, MU-sh and MC-sh was performed as per
standard protocols. Further, quantification of the Western blots (B) revealed significant reductions in protein expressions after M-sh, U-sh, C-sh, MU-sh
and MC-sh treatments. n=3. Values shown are the mean (6SEM). *p,0.05 vs. control (C) Adhesion assay was performed to evaluate the effect of SV-
sh, M-sh, U-sh, C-sh, MU-sh and MC-sh treatments in 4910 and 5310 glioma xenograft cells on their adhesive potential to collagen (type I), vitronectin,
fibronectin and laminin coated plates. Percent adhesion was calculated from the mean obtained from 3 independent experiments and values shown
are the mean (6SEM). *p,0.05 vs. control.
doi:10.1371/journal.pone.0011583.g001
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also with other treatments. In addition, fibrin zymography
revealed prominent reductions in uPA activity with all the
treatments in 4910 cells (Fig. 1A) and further supported the fact
that activity/expression of one protease influence the activity/
expression of other proteases and related molecules. Western blot
analysis results clearly demonstrated significant reductions in
protein expressions of these molecules with all the treatments
except SV-sh compared to control cells (Fig. 1A–B). RT-PCR
analysis of the cDNAs obtained from control and transfected 4910
cells revealed similar kind of reductions in these molecules at
mRNA level (Fig. 1A). Taken together, these experiments at
activity, protein and mRNA levels clearly demonstrate the
efficiency of the shRNA plasmid constructs and the appropriate
transfection conditions in xenograft cells. Reduction in the mRNA
levels of MMP-9, uPAR and cathepsin B in M-sh, U-sh and C-sh
transfected 4910 cells indicated a downregulation of MMP-9,
uPAR and cathespin B target mRNAs, the mechanism by which
shRNAs are proposed to work [24,25]. Bands related to GAPDH
at mRNA and protein levels associated with various treatments in
4910 cells indicate that similar amounts of mRNA/protein were
loaded in all treatment groups.
Downregulation of proteases and uPAR inhibits adhesion
to ECM proteins
Cell adhesion to ECM is a crucial regulator of many functions,
including cell cycle, survival, migration, proliferation, differentia-
tion and ultimately, tumor invasion [4,26]. All the treatments
(M-sh, U-sh, C-sh, MU-sh and MC-sh) inhibited the adhesion of
both the xenografts to collagen, vitronectin, fibronectin and
laminin. M-sh, U-sh and C-sh treatments in these xenografts
significantly inhibited their adhesion to collagen (M-sh-39%, U-sh-
51% and C-sh-57% inhibition in 4910 cells and M-sh-40%, U-sh-
44% and C-sh-59% inhibition in 5310 cells), vitronectin (M-sh-
51%, U-sh-45% and C-sh-57% inhibition in 4910 cells and M-sh-
56%, U-sh-58% and C-sh-58% inhibition in 5310 cells),
fibronectin (M-sh-36%, U-sh-48% and C-sh-48% inhibition in
4910 cells and M-sh-30%, U-sh-37% and C-sh-41% inhibition in
5310 cells), and laminin (M-sh-50%, U-sh-34% and C-sh-45%
inhibition in 4910 cells and M-sh-48%, U-sh-52% and C-sh-65%
inhibition in 5310 cells) (Fig. 1C). As expected, downregulation of
MMP-9 in combination either with uPAR or cathepsin B further
inhibited the adhesion of 4910 and 5310 cells to collagen,
vitronectin, fibronectin and laminin (Fig. 1C). Results of the
adhesion assay suggest bicistronic constructs that can simulta-
neously downregulate two molecules are more effective in
reducing the adhesion of xenografts to various ECM proteins
when compared to the single constructs that can only downreg-
ulate one molecule at a time. Interestingly, MC-sh treatment was
found to be more effective than MU-sh in reducing the adhesion of
both the xenografts to collagen and vitronectin.
Integrins are transmembrane receptors for ECM proteins such
as collagen, fibronectin, vitronectin and laminin. The classic role
of integrins is to anchor cells to the ECM. Upregulation of a2b1,
a3b1, a5b1, a6b1, aVb3 and a9b1 integrins in glioblastoma was
previously reported [27–29]. Hence, in the present study, we
assessed the effect of downregulating uPAR, MMP-9 and
cathepsin B alone and in combination on integrin expression.
Although we have performed RT-PCR analysis by using several
alpha and beta integrin primers, here we presented/discussed only
those integrins that are affected in 4910 cells with shRNA
treatments. All the affected integrins in 4910 cells were tested in
5310 cells and subjected to all the shRNA treatments. RT-PCR
analysis of b1 and b3 integrins in 4910 and 5310 xenografts
treated with various shRNAs for MMP-9, uPAR and cathepsin B
revealed a marked reduction in their respective mRNA expression
levels as compared to the controls (Fig. 2A). All the treatments
downregulated the mRNA levels of b1 and b3 in both the
xenografts except b1 and b3 mRNA levels in M-sh-treated 4910
xenograft cells. However, a significant reduction in these b integrin
mRNA levels was noticed in both the xenografts treated with
bicistronic constructs that simultaneously downregulate MMP-9
and either uPAR or cathespin B (Fig. 2A). The mRNA levels of
several alpha integrins were reduced with MMP-9, uPAR and
cathepsin B downregulation (Fig. 2B). a6, a9 and aV mRNA levels
were downregulated in both the xenograft cell lines under all the
treatment conditions.
Immunocytochemistry of b1 and b3 integrins in 4910 and 5310
xenografts subjected to various shRNA treatments revealed a
marked reduction in their protein expressions with all the
treatments (Fig. 3A). Transfection with a scrambled vector in
either of the xenografts did not affect the expression of these
integrins. Reductions in the protein expressions similar to mRNA
levels were noticed with a6, a9 and aV integrins when the
transfected cells were subjected to immunocytochemistry (Fig. 3B).
a1, a2, a7 and a10 integrins were downregulated only in 4910
xenograft cells treated with U-sh, C-sh, MU-sh and MC-sh (data
not shown). These findings were further strengthened by the
immunoblot analysis results wherein aV, a6, a9, b1 and b3
integrin protein expressions were significantly reduced after MU-
sh and MC-sh treatments in 4910 cells (Fig. 4A–B). Based on these
results and the earlier reported data [27–29], we hypothesize the
involvement of aVb3, a6b1 and a9b1 heterodimer combinations
on the effects mediated by our shRNA treatments in the glioma
xenografts studied in this present investigation. FACS analysis
results clearly demonstrated that 4910 cells express a6b1, a9b1
and aVb3 integrin heterodimers (Fig. 4C). Immunohistochemical
analysis performed on the slide tissue microarrays of clinical GBM
samples revealed the presence of aVb3, a6b1 and a9b1 integrins
on several GBM clinical samples compared to normal cerebrum
(Fig. 4D).
shRNA treatment inhibited the migrating and invasive
potential of glioma xenografts
In control and SV-sh-treated xenografts, 80–90% of the wound
repair occurred within 16 h after creating the wound in 5310 and
4910 cells. Hence, the percent wound repair after treatments with
M-sh, U-sh, C-sh, MU-sh and MC-sh was assessed at 16 h time
point in 5310 and 4910 cells (Fig. 5A). We noticed significant
reduction in percent wound repair with all the treatments in both
the xenografts. Quantification of the results revealed that the
wound reduced to 38%, 57%, 54%, 29% and 1% in 5310 and
51%, 54%, 45%, 43% and 32% in 4910 cells treated with M-sh,
U-sh, C-sh, MU-sh and MC-sh, respectively (Fig. 5C). As assessed
by spheroid migration assay, downregulating individual molecules
using M-sh, U-sh and C-sh reduced migration of cells from the
spheroids (Fig. 5B). Significant and prominent reductions in
migration of the cells from spheroids were noticed upon treatment
with bicistronic constructs MU-sh and MC-sh (Fig. 5D). Quan-
tification of migration of the cells from spheroids revealed 67%,
83%, 58%, 61% and 23% reduction in 4910 and 50%, 53%, 50%,
38% and 30% reduction in 5310 cells treated with M-sh, U-sh, C-
sh, MU-sh and MC-sh, respectively (Fig. 5D). The most dangerous
feature of malignancy is invasive and metastatic potential.
Simultaneous downregulation of MMP-9 along with either uPAR
or cathepsin B reduced the invasive potential of 4910 and 5310
cells through the Matrigel (Fig. 5E). Quantification of Matrigel
invasion assay results revealed a significant reduction in invasive
Silencing Proteases in Glioma
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the bicistronic constructs (Fig. 5F).
Involvement of a9b1 on the migration potential of
xenograft cells
Comparedto aVb3a n da6b1 integrins, very little isknown about
the role a9b1 integrin in glioma. We studied the effect of a9b1
blockade on the migratory potential of 5310 cells that are
transfectedwithuPAR,MMP-9and cathepsinBexpressing plasmid
DNAs. RT-PCR analysis of uPAR, MMP-9 and cathepsin B in
4910 and 5310 cells transfectedwithuPAR expressing (U-fl), MMP-
9 expressing (M-fl) and cathepsin B expressing (C-fl) plasmid DNAs
clearly demonstrated the efficiency of the constructs and transfec-
tions(Fig.6A–B).Asexpected,significantincreaseinpercent wound
repair noticed with U-fl, M-fl and C-fl treatments in 5310 cells
which was significantly blocked with the same treatments in
presence ofa9b1 antibody(Fig. 6C–D).Furthermore,a9b1 integrin
levels as revealed by FACS analysis were significantly reduced after
MU-sh and MC-sh treatments in 4910 cells (Fig. 6E). These results
clearly demonstrate the involvement of a9b1 in uPAR, MMP-9 and
cathepsin B mediated migration in glioma xenograft cells.
Effect of bicistronic constructs on proliferation in vitro
and tumors in vivo
MU-sh and MC-sh treatments efficiently reduced the colony
forming ability of 4910 and 5310 cells (Fig. 6F). Similarly,
proliferation of 4910 cells as evidenced by MTT assay was
significantly reduced on Days 4, 5 and 6 after MU-sh and MC-sh
treatments compared to untreated 4910 cells (Fig. 6G).
Hematoxylin and eosin staining performed on mouse brains
(injected with xenograft cells 2 weeks before treatment) revealed a
prominent reduction of tumor growth in MU-sh and MC-sh
treated mouse brains when compared to the controls (Fig. 7A).
Aggressive tumor formation was noticed in xenografts injected
mouse brains compared to normal brains (Fig. 7A–B). Further-
more, the apoptotic index of tumor cells quantified by the number
of positive cells for TUNEL staining showed a drastic and
significant increase in the number of apoptotic cells in the tumor
sections from mice that were treated with bicistronic constructs
(data not shown). Brains of the animals that were sacrificed 2–3
weeks prior to the end of the treatment were used to evaluate the
effect of MU-sh and MC-sh treatments on the expression of aVb3,
a6b1 and a9b1 integrins. As expected, prominent reduction of
aVb3, a6b1 and a9b1 integrin expression was noticed on the
5310 in vivo tumors that were treated with MU-sh and MC-sh
(Fig. 7C). Immunohistochemical analysis of platelet endothelial
cell adhesion molecule (PECAM-1) performed on the brain
sections of 4910 and 5310 control tumors and MU-sh and MC-
sh treated 5310 tumors (from the animals that are sacrificed 2–3
weeks prior to the end of the treatment) revealed that the extent of
blood vessels in 4910 and 5310 untreated tumors are more
compared to MU-sh and MC-sh treated 5310 tumors (Fig. 7D).
Effect of silencing proteases and uPAR on FAK and other
migration molecules
Our results clearly demonstrated the involvement of aVb3,
a6b1 and a9b1 and integrins in the effects mediated by shRNA
treatments and thereby affected the adhesive, migrating and
invasive potential of glioma xenografts. To further confirm the
Figure 2. RT-PCR analysis of integrins. (A) RT-PCR analysis of 4910 and 5310 cells transfected with scrambled vector (SV-sh), MMP-9 (M-sh), uPAR
(U-sh), cathepsin B (C-sh), MMP-9/uPAR (MU-sh) and MMP-9/cathepsin B (MC-sh) plasmid shRNAs, showing the mRNA expressions of b integrins (b1
and b3) (A) and a integrins (a1, a2, a6, a7, a9, a10, and aV) (B).
doi:10.1371/journal.pone.0011583.g002
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shRNA treatments on the signaling molecules associated with
integrin mediated migration. Hence, we evaluated the effect of
MU-sh and MC-sh treatments on several molecules such as FAK,
talin1, talin2, profilin, vinculin, actinin, tensin, Rac1 and Arp2 in
both the xenograft cell lines by using RT-PCR analysis.
Downregulation of FAK, talin1, talin 2, profilin, tensin and
Arp2 was noticed in treated 5310 cells whereas in 4910 cells, FAK,
talin1, talin2, vinculin, actinin, tensin and Arp2 levels were
reduced with both MU-sh and MC-sh treatments (Fig. 8A). Rac1
mRNA levels reduced only in MC-sh treated 5310 cells. Further,
vinculin and actinin mRNA levels reduced only in 4910 cells
treated with these bicistronic constructs. The expressions of FAK,
phospho-FAK, cSrc, phospho-Src, Arp2, F-actin, paxillin, phos-
pho-paxillin at protein level were reduced with both MU-sh and
MC-sh treatments in 5310 cells (Fig. 8B). Rac1, talin1, a-actinin
and vinculin protein expressions were reduced only in MC-sh
treated 5310 xenografts. MU-sh and MC-sh treatments did not
affect cofilin levels. In agreement with our adhesion, migration and
invasion assay results, a more pronounced downregulation was
noticed in majority of the migration-related molecules with MC-sh
as compared to MU-sh.
Discussion
Malignant gliomas are highly invasive neoplasms. They may
make a permissive environment for invasion by synthesizing and
depositing an autologus matrix that facilitates their own motility.
The ECM, which is a key component of the tissue destroyed
during tumor cell invasion, is a dynamic environment that has a
Figure 3. Effect of shRNA plasmid constructs on the expression of integrins at protein level. (A) Immunocytochemistry was performed to
evaluate the effect of various shRNA treatments on the expressions of b1 and b3 integrins. Microscopic images demonstrate b1 and b3 integrin
expressions (red fluorescence) in 4910 and 5310 cells transfected with scrambled vector (SV-sh), MMP-9 (M-sh), uPAR (U-sh), cathepsin B (C-sh), MMP-
9/uPAR (MU-sh) and MMP-9/cathepsin B (MC-sh). All treatments reduced b1 and b3 integrins expression. (B) The effect of various shRNA treatments
on the expressions of a6, a9 and aV integrins was also evaluated and the microscopic images demonstrate a6, a9 and aV integrins expression in 4910
and 5310 cells transfected with SV-sh, M-sh, U-sh, C-sh, MU-sh and MC-sh. All the treatments reduced a6, a9 and aV integrins expression in both the
cell lines.
doi:10.1371/journal.pone.0011583.g003
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PLoS ONE | www.plosone.org 5 July 2010 | Volume 5 | Issue 7 | e11583Figure 4. Effect of bicistronic constructs on integrins and the expression of aVb3, a6b1a n da9b1 integrins on glioma xenografts and
GBM clinical samples. (A) Westernblotanalysisdepictingthe reducedproteinexpressions ofaV, a6,a9,b1a n db3 integrins after MMP-9/uPAR (MU-sh)
and MMP-9/cathepsin B (MC-sh) plasmid shRNA treatments in 4910 cells. n=3. Further, quantification of the Western blots (B) revealed significant
reductions in protein expressions after MU-sh and MC-sh treatments. n=3. Values shown are the mean (6SEM). *p,0.05 vs. control. (C) FACS analysis
showingthe presence ofaVb3,a6b1a n da9b1 integrin heterodimers on4910glioma xenogaft cells. 4910cells, in which isomatchmouse IgG usedasthe
primaryantibodyservedasnegativecontrols.NC-negativecontrol(D)Immunohistochemistryofnormalcerebrumandglioblastomamultiforme(GBM)for
aVb3, a6b1a n da9b1 integrin heterodimer expressions. GBM tissue micro arrays were processed for immunohistochemistry. Prominent brown staining
indicative of aVb3, a6b1o ra9b1 integrin expression was noticed in GBM samples. Scale bar=100 mm.
doi:10.1371/journal.pone.0011583.g004
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remodeling processes, such as tumor invasion and metastasis.
Tumor ECM and basement membranes of tumor blood vessels
have shown tenacin, vitronectin, collagens, fibronectin, laminin,
hyaluronan, chondroitin sulfate and heparan sulfate. Collagen,
laminin, tenacin, fibronectin and vitronectin serve as permissive
substrates for glioma cell migration. Cell adhesion plays a major
role in regulating cell movement. Adhesion of glioma xenograft
cells to various components of ECM such as collagen, vitronectin,
fibronectin and laminin was significantly inhibited by MMP-9,
uPAR and cathepsin B shRNA plasmid constructs. Simultaneous
targeting of multiple molecules has been more synergistic than
additive [30]. As expected, inhibition of adhesion of these cells to
ECM components is much more significant with the simultaneous
downregulation of MMP-9 and uPAR or MMP-9 and cathepsin
B.
Integrins expressed in tumor cells contribute to tumor
progression and metastasis by increasing tumor cell migration,
invasion, proliferation and survival [8]. Integrin adhesion to ECM
provides the traction required for tumor cell invasion. Interactions
and signaling mechanisms among uPAR, MMP-9 and cathepsin B
associated with integrin involvement were well studied and
reported [31–34]. Integrins are essential uPAR signaling co-
receptors and the interactions between uPAR/b1 and uPAR/b3
have an important role in signaling for cell migration and invasion
[34]. It was reported that the cleavage of aV integrin subunit
precursor by MMP-14 enhanced cancer-cell migration [35].
Further, cooperation between MMP-9 and integrins is known to
activate aVb3, which strongly enhanced tumor migration [36].
Cathepsin B is known to be associated with uPAR and its integrin-
mediated signaling ability [37]. Moreover, immunoprecipitation of
the 4910 and 5310 glioma xenograft cell lysates with b1 integrin
followed by immunoblot analysis with cathepsin B indicated a
possibility for the direct or indirect interaction between these two
molecules (data not shown). Inhibition of adhesion by MMP-9,
uPAR and cathepsin B silencing in the present study resulted in a
significant reduction in the expressions of several alpha and beta
integrins both at mRNA and protein levels. aV, a6, a9, b1 and b3
integrin mRNA and protein expressions were prominently
downregulated in both the xenograft cell lines with all the
treatments. Upregulation of a2b1, a3b1, a5b1, aVb3 and a6b1
integrins on GBM have already been reported [28,29]. In 2008,
deHart et al., identified that a9b1 integrin increase cell migration
by modulation of polyamine metabolism and activation of
potassium channels [38]. Unlike other integrin heterodimers,
a9b1 was able to both increase cell migration and inhibit cell
spreading [39,40]. It was recently found that a9b1 integrin played
a significant role in the progression of glioblastoma [27]. Hence,
we expected the involvement of aVb3, a6b1 and a9b1
heterodimer combinations on the effects mediated by our shRNA
treatments in the xenografts studied in our present investigation.
FACS analysis confirmed the expression of aVb3, a6b1 and a9b1
integrins on xenograft cells. Bicistronic constructs significantly
reduced a9b1 levels in vitro in 4910 cells. These constructs also
reduced the proliferation of xenograft cells in vitro. In vivo studies in
nude mice injected with 5310 cells revealed a prominent
reductions in the expression of integrin heterodimers (aVb3,
a6b1 and a9b1) when treated with MMP-9/uPAR or MMP-9/
cathepsin B shRNAs. Furthermore, drastic reductions in tumor
growth and extent of blood vessels in tumor mass (neoangiogen-
esis) were noticed in vivo after MU-sh and MC-sh treatments in
xenograft cells injected nude mice. These results are in agreement
with our earlier reports, wherein we have noticed a significant
decrease in tumor growth with MU-sh and MC-sh treatments in
SNB19 cells injected mouse brains [33,41].
a9b1 has distinguished its functionality from other integrins
(aVb3 and a3b1) by facilitating accelerated cell migration [42].
Hence, in the present study, we performed spheroid migration
assay and wound healing assay in order to address the effect of
silencing proteases on migratory potential of glioma xenografts. All
the treatments with single (M-sh, U-sh and C-sh) and bicistronic
constructs (MU-sh and MC-sh) significantly reduced the migration
of glioma xenografts in all the above-mentioned assays. Our results
clearly revealed that the bicistronic constructs were more effective
than the single constructs in reducing the migrating potential of
glioma xenografts. Further, in concurrence with adhesion assay
results, we have noticed a marked reduction in migration in all the
assays with MC-sh as compared to MU-sh. Integrin a9b1i s
classified within a two member sub-family of integrins highlighted
in part by its specialized role in cell migration [43]. Unlike other
integrins, a9b1 has been proposed to utilize inducible nitric oxide
synthase (iNOS)-nitric oxide (NO) and spermidine/spermine
acetyl transferase (SSAT)-inward rectifier potassium channel
(Kir) pathways along with common integrin signaling proteins
such as Src and FAK to transduce cell migration [43]. Significant
inhibition of uPAR, MMP-9 and cathepsin B mediated migration
in 5310 xenograft cells by a9b1 integrin blockade, clearly
demonstrated its possible role. Gliomas are highly invasive and
the invasive nature of gliomas has an important role in the
ineffectiveness of current treatment modalities, as the remaining
cancer cells inevitably infiltrate the surrounding normal brain
tissue and lead to tumor recurrence [37]. Hence, we felt it is
crucial to evaluate the effect of shRNA treatments on the invasive
potential of xenografts and as expected, the MU-sh and MC-sh
treatments significantly inhibited the invasion of both 4910 and
5310 cells through the Matrigel.
In this study, downregulation of uPAR and the proteases,
MMP-9 and cathepsin B showed a significant reduction in the
adhesion, migration and invasive potential of xenografts and also
affected the levels of several alpha and beta integrins. Like other
integrins a9b1 ligation can activate signaling through Src and
FAK mediated tyrosine phosphorylation of multiple proteins
including p130Cas and paxillin [40,44]. Hence, we suspected that
our treatments played a significant role in regulating the molecules
associated with integrin-mediated signaling that leads to migra-
tion. Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase
Figure 5. Wound healing, spheroid migration and Matrigel invasion assays. (A) Reduction in wound healing indicative of reduced
migration potential was noticed after treatments with MMP-9 (M-sh), uPAR (U-sh), cathepsin B (C-sh), MMP-9/uPAR (MU-sh) and MMP-9/cathepsin B
(MC-sh) plasmid shRNAs in both 4910 and 5310 cells. Untreated and SV-sh transfected cells served as controls. (B) Migration of the cells from 4910
and 5310 spheroids transfected with M-sh, U-sh, C-sh, MU-sh and MC-sh was prominently reduced. (C, D) Quantification of wound healing and
spheroid migration assays. Percent wound repair was calculated from the mean of the average width of the wound obtained from 3 independent
experiments. Similarly, percent migration was calculated from the mean of the average migration obtained from 3 independent experiments. Error
bars indicate SEM. *p,0.05 vs. control. (E) Matrigel invasion assay of 4910 and 5310 cells transfected with SV-sh, MU-sh and MC-sh. MU-sh and MC-sh
treatments prominently reduced the invasive potential of both 4910 and 5310 cells through Matrigel. (F) Invasion was quantified by counting the
average number of invaded cells in five different fields with each treatment. Percent invasion was calculated from the mean of the average number of
invaded cells obtained from 3 independent experiments. Error bars indicate SEM. *p,0.05 vs. control.
doi:10.1371/journal.pone.0011583.g005
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signal transduction pathways [5,45]. The most important
transmembrane receptors associated with uPAR signaling are
the integrin family of ECM receptors [34]. uPAR/b1 integrin
interactions are frequently associated with the activation of FAK
and ERK, whereas uPAR/b3 integrin interactions are associated
with the activation of Rac [20,46–48]. Prominent reduction in
FAK mRNA levels with MU-sh and MC-sh treatments in both the
xenograft cell lines in the present study demonstrated the
involvement of integrins via FAK in inhibiting their adhesion
and migration potential. Even though the migration potential of
both the xenografts was significantly reduced with all the shRNA
treatments, they behaved differently in regulating the mRNA
expressions of various genes associated with migration. Reduced
FAK, phospho-FAK, cSrc, phospho-Src, Arp2, F-actin, paxillin,
phospho-paxillin protein levels after treatment with bicistronic
constructs in 5310 cells further strengthened our hypothesis that
our treatments inhibit the migratory potential of these xenografts.
Taken together, our findings clearly demonstrated that shRNA-
mediated silencing of MMP-9, uPAR, and cathepsin B inhibited
adhesive, migrating and invasive potentials of glioma xenografts.
Bicistronic constructs that can simultaneously downregulate
MMP-9 and uPAR or MMP-9 and cathepsin B were more
effective than any of the single constructs. We also show the
involvement of several integrins, FAK and associated molecules in
the effects mediated by our shRNA constructs. Furthermore, for
Figure 6. Involvement of a9b1 integrin on the migration potential of xenograft cells and the effect of bicistronic constructs on the
glioma xenograft cell proliferation. (A) RT-PCR of 5310 and 4910 cells transfected with uPAR (U-fl), MMP-9 (M-fl), and cathepsin B (C-fl) expressing
plasmid DNAs was performed as perstandard protocols. Prominent increase in respective mRNA expressions noticed after U-fl, M-fl, and C-fl treatments.
Further, quantification of the RT-PCR data (B) revealed significant increases in uPAR mRNA and MMP-9 mRNA expression after treatments with M-fl and
C-fl, respectivelyin both thexenograftcells.(C)Woundhealing indicative of increasedmigrationpotential noticedaftertreatments withU-fl, M-fl,andC-
fl in 5310 cells was reduced with the same treatments in presence of a9b1 antibody. Photographs are the representative images obtained from three
independent experiments. (D) Quantification of wound healing assay. Percent wound repair was calculated from the mean of the average width of the
wound obtained from 3 independent experiments. Error bars indicate SEM. *p,0.05 vs. control.
#p,0.05. (E) FACS analysis showing reduced a9b1
integrin levels in 4910 cells after MMP-9/uPAR (MU-sh) and MMP-9/cathepsin B (MC-sh) treatments. (F) Clonogeneic assay depicting the reduced
proliferation of 4910 and 5310 cells after MU-sh and MC-sh treatments. After 14 days of incubation, the colonies containing more than 50 cells were
counted. Images shown are the representatives obtained from three independent experiments. (G) MTT assay showing significant reduction in the
proliferation of 4910 cells from Day 4 to Day 6 after MU-sh and MC-sh treatments. n=3. *p,0.05 vs. control.
doi:10.1371/journal.pone.0011583.g006
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the effects mediated by MMP-9, uPAR and cathepsin B silencing
in glioma xenografts. Considering the existence of integrin
inhibitor-resistant cancer cells, our study provides a novel and
effective approach for inhibiting integrins while downregulating
MMP-9, uPAR and cathepsin B in treating glioma.
Materials and Methods
Ethics Statement
The Institutional Animal Care and Use Committee of the
University Of Illinois College Of Medicine at Peoria, Peoria, IL,
USA approved all surgical interventions and post-operative animal
care. The consent was written and approved. The approved
protocol number is 851, dated November 20, 2009.
Cell culture and transfection conditions
The xenograft cell lines (4910 and 5310) were kindly provided
by Dr David James at University of California, San Francisco.
These xenografts were generated and maintained in mice and are
highly invasive in mouse brain [49]. 4910 and 5310 xenografts
were maintained in RPMI 1640, supplemented with 10% fetal
bovine serum, 50 mg/ml streptomycin and 50 U/ml penicillin in a
humidified atmosphere containing 5% CO2 at 37uC. Xenografts
were transfected with SV-sh (scrambled vector), M-sh (MMP-9),
U-sh (uPAR), C-sh (cathepsin B), MU-sh (MMP-9 and uPAR) or
MC-sh (MMP-9 and cathepsin B) shRNA expressing plasmids
using FugeneH HD reagent (Roche Diagnostics, Indianapolis, IN)
as per the manufacturer’s instructions. After transfection, cells
were incubated in serum-containing medium for a minimum of
60 h.
Construction of shRNA and gene expressing plasmids
Plasmid shRNAs for MMP9, uPAR, cathespin B, MMP-9/
uPAR and MMP-9/CathespinB designed in our laboratory
[31,41,50] were used to transfect the xenograft cells. Briefly, a
pCDNA-3 plasmid with a human cytomegalovirus (CMV)
Figure 7. Effect of treatment with bicistronic constructs on the brain tumors in nude mice pre-injected with xenograft cells. (A)
shRNA mediated regression of pre-established tumor growth. Hematoxylin and eosin staining performed on the brain sections obtained from various
groups of animals revealed a prominent tumor reduction after MMP-9/uPAR (MU-sh) or MMP-9/cathepsin B (MC-sh) treatments. Each group consisted
of 6 animals. Yellow curved line in 4910 and 5310 control brain sections indicate the tumor area. (B) Normal nude mice brain section stained with
hematoxylin and eosin. (C) Immunohistochemical comparison of control, MU-sh and MC-sh-treated nude mice which are pre-injected with 5310 cells
(and sacrificed 2–3 weeks prior to the end of the treatment), to analyze the expression of aVb3, a6b1 and a9b1 integrin heterodimers. Brown staining
indicative of aVb3, a6b1o ra9b1 integrin expression was reduced in MU-sh and MC-sh treated sections compared to controls. n=6. Scale
bar=50 mm. (D) Untreated 4910 and 5310 in vivo tumors were prominently stained for platelet endothelial cell adhesion molecule (PECAM-1)
whereas the intensity of brown staining was reduced in 5310 in vivo tumors after MU-sh and MC-sh treatments.
doi:10.1371/journal.pone.0011583.g007
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pCDNA3-scrambled vector with an imperfect sequence, which
does not form a perfect hairpin structure, was used as a control
(SV-sh). MMP-9 expressing (M-fl) plasmids in pDNR-CMV vector
were designed and constructed in our laboratory whereas uPAR
expressing (U-fl) and cathepsin B expressing (C-fl) plasmids were
purchased from Origene (Rockville, MD).
Antibodies
Several antibodies were used in various techniques such as
Western blot, immunocytochemistry, immunohistochemistry and
fluorescent-activated cell sorting (FACS) analysis while determin-
ing the changes in protein expression associated with various
treatments. Antibodies targeting MMP-9, b3 integrin, a6 integrin,
a9 integrin, a9b1 integrin, PECAM-1, FAK, Phospho FAK (Tyr
397), cSrc, talin1, vinculin were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA); Phospho Src (Tyr 527), Arp2,
paxillin, phospho paxillin, cofilin were obtained from Cell
Signaling (Boston, MA); b1 integrin, a6b1 integrin, aVb3 integrin
were obtained from Millipore (Billerica, MA); uPAR was obtained
from R&D Systems (Minneapolis, MN); a-actinin was obtained
from Sigma (St. Louis, MO); cathepsin B was obtained from
Athens Research and Technology (Athens, GA); aV integrin, F-
actin were obtained from Abcam (Cambridge, MA); aVb3
Figure 8. RT PCR and Western blot analysis of the molecules associated with integrin-mediated migration. (A) RT-PCR of 4910 and 5310
glioma xenograft cells transfected with scrambled vector (SV-sh), MMP-9/uPAR (MU-sh) and MMP-9/cathepsin B (MC-sh) plasmid shRNAs was
performed as per standard protocol described in materials and methods. Several genes were downregulated with MU-sh and MC-sh treatments in
both the xenograft cells. Results presented are the representative images of three independent experiments. (B) Western blot analysis showing the
effect of bicistronic constructs (MU-sh and MC-sh) on the protein expressions of FAK, p-FAK (Tyr397), cSrc, p-Src (Tyr527), Rac1, Arp2, F-actin, talin1,
paxillin, p-paxillin (Tyr118), a-actinin, cofilin and vinculin in 5310 human glioma xenograft cells. The expressions of majority of the proteins associated
with integrin-mediated migration were reduced with MU-sh and MC-sh treatments. n=3.
doi:10.1371/journal.pone.0011583.g008
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and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
obtained from Novus Biologicals (Littleton, CO).
Gelatin zymography
MMP-9 activity in the conditioned medium was determined by
gelatin zymography. 4910 and 5310 human glioma xenograft cells
were transfected with SV-sh, M-sh, U-sh, C-sh, MU-sh and MC-
sh for 72 h. Cells were washed and incubated with serum-free
medium overnight. Equal amounts of protein were electropho-
resed in 10% SDS-polyacrylamide gels containing 1.5 mg/mL
gelatin. The gels were washed and gently shaken in three
consecutive washings in 2.5% Triton X-100 solution to remove
SDS. The gels were then incubated at 37uC overnight in
incubation buffer [50 mmol/l Tris-HCl (pH 7.5), 0.05% NaN3,
5 mmol/l CaCl2 and 1 mmol/l ZnCl2]. Next, the gels were
stained with 0.1% amido black in 10% acetic acid and 10%
isopropanol and subsequently destained for 1 h. Gelatinolytic
activities were identified as clear zones of lysis against a dark
background.
Fibrinogen zymography
4910 and 5310 human glioma xenograft cells were transfected
with SV-sh, M-sh, U-sh, C-sh, MU-sh or MC-sh for 72 h. Cells
were washed and incubated with serum-free medium overnight.
Conditioned media was collected and zymography was performed
to determine uPA activity. Equal amounts of protein samples were
resolved on 10% SDS-polyacrylamide gels containing plasminogen
and fibrinogen and stained with 0.1% amido black in 10% acetic
acid and 10% isopropanol and subsequently destained for 1 h.
Western blot analysis
Xenograft cells were transfected with SV-sh, M-sh, U-sh, C-sh,
MU-sh or MC-sh for 72 h. Cells were collected and lysed in RIPA
buffer [50 mmol/ml Tris-HCl (pH 8.0), 150 mmol/ml NaCl, 1%
IGEPAL, 0.5% sodium deoxycholate, 0.1% SDS] containing
1 mM sodium orthovanadate, 0.5 mM PMSF, 10 m/ml aprotinin,
10 mg/ml leupeptin and resolved via SDS-PAGE. After overnight
transfer onto nitrocellulose membranes, blots were blocked with
5% non-fat dry milk in PBS and 0.1% Tween-20. Blots were then
incubated with primary antibody, followed by incubation with
HRP-conjugated secondary antibody. Immunoreactive bands
were visualized using chemiluminescence ECL Western blotting
detection reagents on Hyperfilm-MP autoradiography film
(Amersham, Piscataway, NJ). GAPDH (housekeeping gene)
antibody was used to verify that similar amounts of protein were
loaded in all lanes.
Reverse transcription PCR analysis
4910 and 5310 cells were transfected with SV-sh, M-sh, U- sh,
C-sh, MU-sh, MC-sh, U-fl, M-fl or C-fl. The cells were collected
and total cell RNA was isolated. Approximately 500 ng of total
RNA from each sample was synthesized into cDNA as per the
manufacturer’s instructions using the Transcriptor First Strand
cDNA Synthesis Kit (Roche Diagnostics, Indianapolis, IN). We
used the following sequences for the forward and reverse primers:
N for MMP-9, 59CTCGAACTTTGACAGCGACA39 (forward)
and 59GCCATTCACGTCGTCCTTAT39 (reverse);
N for uPAR, 59GCCTTACCGAGGTTGTGTGT39 (forward)
and 59CATCCAGGCACTGTTCTTCA39 (reverse);
N for cathepsin B, 59GCTACAGCCCGACCTACAAA39 (for-
ward) and 59CCAGTAGGGTGTGCCATTCT39 (reverse);
N for integrin aV, 59CACCAGCAGTCAGAGATGGA39 (for-
ward) and 59GAACAACTGGCCCAACATCT39 (reverse);
N for integrin a1, 59GTCCAGTTGGGAGAGGTGAA39 (for-
ward) and 59ACTTGAAATGTGGGGCTGAC39 (reverse);
N for integrin a2, 59CAAGTGGGATTCAGTGCAGA39 (for-
ward) and 59GAGCACCAGCAACAAAGTGA39 (reverse);
N for integrin a6, 59CCCCGCTGGTTATAATCCTT39 (for-
ward) and 59GGTTTCCTCCATGCACACTT39 (reverse);
N for integrin a7, 59GGGAACCAATACCCTGACCT39 (for-
ward) and 59CTATAGCTGCTGGGGACTGC39 (reverse);
N for integrin a9, 59CGGAATCATGTCTCCAACCT39 (for-
ward) and 59CTCTGCACCACCAGATGAGA39 (reverse);
N for integrin a10, 59CAACAGCATCTACCCCTGGT39 (for-
ward) and 59GGTTCTTTGCTGCTCTCACC39 (reverse);
N for integrin b1, 59CATCTGCGAGTGTGGTGTCT39 (for-
ward) and 59GGGGTAATTTGTCCCGACTT39 (reverse);
N for integrin b3, 59GCAATGGGACCTTTGAGTGT39 (for-
ward) and 59GTGGCAGACACATTGACCAC39 (reverse);
N for FAK, 59AGCTGATTGGAGTCATCACAGA39 (forward)
and 59GAGGGTAGGAGGACAATTTGG39 (reverse);
N for talin1, 59TGGAGAACTCAAAGGTGCTG39 (forward)
and 59CGCCTTGATGGTCTTGACA39 (reverse);
N for talin2, 59CACACTGGATTTTGGGGAGT39 (forward)
and 59ATATCCTGGCCGAGAGGTG39 (reverse);
N for profilin, 59AACGTTCGTCAACATCACG39 (forward)
and 59TTTGGCAGCAATAAGGGGTA39 (reverse);
N for vinculin, 59TACGAAGACAGGGGAAAGGA39 (forward)
and 59TTGGAGCTGAGATGCAAGTG39 (reverse);
N for actinin, 59GGCCAGTGATCTGTTGGAGT39 (forward)
and 59TAGTCCTTCTGTCGCAGCAT39 (reverse);
N for tensin, 59AGACACCCCTGTCTGCTCTG39 (forward)
and 59GGGAAACTCCCCACTGAAG39 (reverse);
N for Rac1, 59GGGAGACGGAGCTGTAGGTA39 (forward)
and 59CAGCACCAATCTCCTTAGCC39 (reverse);
N for Arp2, 59CTTCTGTTGCGAGGATACGC39 (forward)
and 59AAGTTTTTCCACATCACCCTTC39 (reverse);
N for GAPDH, 59AGCCACATCGCTCAGACACC39 (for-
ward) and 59GTACTCAGCGGCCAGCATCG39 (reverse);
N for b-actin, 59GGCATCCTCACCCTGAAGTA39 (forward)
and 59GGGGTGTTGAAGGTCTCAAA39 (reverse);
Reverse transcriptase PCR was set up using the PCR cycle
[95uC for 5 min, (95uC for 30 sec, 55–60uC for 30 sec, and 72uC
for 30 sec)630 cycles, 72uC for 10 min]. PCR products were
resolved on a 1.6% agarose gel, visualized, and photographed
under UV light.
Adhesion Assay
Adhesion was assessed as described previously [51] with
modifications. 4910 and 5310 human glioma xenograft cells
(1610
6) were seeded on 100-mm culture plates and incubated in a
humidified atmosphere containing 5% CO2 at 37uC. 24 h after
incubation, cells were transfected with SV-sh, M-sh, U-sh, C-sh,
MU-sh or MC-sh. 72 h after transfection, cells were harvested by
50 mM EDTA treatment, washed with PBS, then resuspended in
10% serum-containing medium for 1 h at 37uC. Cells were
washed twice with serum-free medium, resuspended in serum-free
medium, and seeded at 30,000–50,000 cells/well in a 96-well plate
coated with various components of extracellular matrix (ECM)
such as collagen (type I), fibronectin, vitronectin or laminin. After
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rinsing the slides three times with PBS. The remaining attached
cells were fixed and stained with Hema-3 (Fisher Scientific).
Images in 5 different fields covering a majority of the area in each
well of a 96-well plate were taken from all the treatment groups
under a light microscope. The number of adhered cells from all
the treatment groups was counted and the average was recorded
for comparative quantification.
Spheroid migration assay
4910 and 5310 spheroids were cultured in 96-well plates
coated with 1% agar. Briefly, 3610
4 cells/well were seeded and
cultured on a shaker at 100 rpm for 48 h in a humidified
atmosphere containing 5% CO2 at 37uC. After the formation of
spheroids, they were transfected with SV-sh, M-sh, U-sh, C-sh,
MU-sh or MC-sh. 48 h after transfection, the spheroids were
transferred to 24-well plates and incubated at 37uC. Twenty four
hours after incubation, the spheroids were fixed and stained with
Hema-3. Cell migration from the spheroids was assessed using
light microscopy. The migration of cells from spheroids to
monolayers was used as an index of cell migration and was
measured using a microscope calibrated with a stage and ocular
micrometer.
Wound healing assay
To study cell migration, we seeded xenograft cells (4910 and
5310) at a density of 2610
6 in a 6-well plate and transfected the
cells with SV-sh, M-sh, U-sh, C-sh, MU-sh or MC-sh for 72 h.
Then, a straight scratch was made in individual wells with a
200 mL pipette tip. This point was considered the ‘‘0 h,’’ and the
width of the wound was photographed under the microscope.
After 6–16 h, the cells were checked for wound healing and
photographed at 16 h under the microscope. Wound healing was
measured by calculating the reduction in the width of the wound
after incubation. We also studied the effect of U-fl, M-fl and C-fl
treatments in the absence and presence of a9b1 antibody on
migration in 4910 cells by performing this assay.
Matrigel invasion assay
4910 and 5310 cells were transfected with SV-sh, MU-sh or
MC-sh for 72 h. Cells were trypsinized and 5610
4 cells were
placed onto Matrigel-coated transwell inserts with 8-mm pore size.
Cells were allowed to migrate through the Matrigel for 24 to 48 h.
Then, cells in the upper chamber were removed with a cotton
swab. The cells that adhered on the outer surface of the transwell
insert and had invaded through the matrigel were fixed, stained
with Hema-3, and counted under a light microscope as described
previously [52].
Immunocytochemistry
4910 and 5310 cells (1610
4) were seeded on 2-well chamber
slides, incubated for 24 h, and transfected with SV-sh, M-sh, U-sh,
C-sh, MU-sh or MC-sh for 72 h. Then, cells were fixed with 10%
buffered formalin phosphate and incubated with 1% bovine serum
albumin in PBS at room temperature for 1 h for blocking. After
the slides were washed with PBS, primary antibodies were added
at a concentration of 1:100. The slides were incubated overnight at
4uC and washed thrice with PBS to remove excess primary
antibody. Cells were then incubated with Alexa FluorH 594 (goat
anti-mouse IgG, red) fluorescent-labeled secondary antibody for
1 h at room temperature. The slides were then washed thrice with
PBS and covered with glass coverslips, and fluorescent photomi-
crographs were obtained.
Immunohistochemistry
Paraffin embedded brain sections (5 mm thick) from control and
treatment groups were deparaffinized as per standard protocol.
The sections were rinsed with PBS and treated with 1% BSA in
PBS to prevent nonspecific staining and incubated with primary
antibodies (1:50 dilution) at 4uC overnight. The sections were then
washed in PBS and incubated with appropriate HRP-conjugated
secondary antibodies for 1 h at room temperature. After 1 h,
sections were washed in PBS and incubated in DAB for 30 min.
The slides were further washed with sterile water and subjected to
dehydration. After dehydration, the slides were stained with
hematoxylin to visualize the nucleus, mounted and observed under
a light microscope. Immunohistochemical analysis for aVb3, a6b1
and a9b1 integrins was performed on the slide tissue microarrays
(obtained from US Biomax, Inc., Rockville, MD, USA) of clinical
GBM samples.
FACS analysis
4910 cells (2610
6) were seeded on 100-mm tissue culture plates,
incubated for 48 h, and then treated with 50 mM EDTA, washed
with PBS, pelleted at 1000 rpm for 5 min, and resuspended at a
concentration of 1610
6 cells/mL in PBS. Cells were then
incubated with HRP-conjugated or fluorescence conjugated
primary antibodies for 1 h on ice, pelleted, and washed three
times with PBS to remove excess primary antibody. Cells that were
incubated with HRP-conjugated primary antibodies were then
resuspended in 1 ml of PBS and incubated with Alexa FluorH 594
(goat anti-mouse IgG, red) fluorescent labeled secondary antibody
for 1 h on ice. After three more washes in PBS, cell pellet was
resuspended in 10% buffered formalin and analyzed on a Coulter
EPICS XL AB6064 flow cytometer (Beckman Coulter, Fullerton,
CA). We also studied the effect of MU-sh and MC-sh treatments in
4910 cells on a9b1 integrin levels by performing FACS analysis.
Clonogenic assay
To study the effect of bicistronic plasmid shRNA treatments on
proliferation, 4910 and 5310 cells were transfected with SV-sh,
MU-sh or MC-sh. 72 h after transfection, cells were plated on
100-mm plates at 2000 cells per plate. Medium was subsequently
changed every 3 days. After 2 weeks, the resulting colonies were
fixed and stained with Hema-3, and counted as a measure of
clonogenecity.
Cell proliferation assay
Cell growth was assessed by MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay. 4910 cells were transfect-
ed with SV-sh, MU-sh or MC-sh. 72 h after transfection, 5610
3
cells were seeded in triplicate into 96-well plates and incubated
different time intervals. Before each time point, we added 10 mlo f
5 mg/ml freshly prepared MTT reagent to each well and
continued the incubation for an additional 2 h to permit color
development. After incubation, the crystals were dissolved in 2-
propanol + hydrochloric acid solution and the plate was left in
dark for 3 h. After 3 h, absorbance was measured using Biorad
Microplate Reader.
Intracranial administrations in nude mice
The Institutional Animal Care and Use Committee of the
University Of Illinois College Of Medicine at Peoria, Peoria, IL,
USA approved all surgical interventions and post-operative animal
care. 4910 and 5310 xenografts were trypsinized and resuspended
in serum free medium at a concentration of 0.2610
5 cells/mL.
Nude mice were injected intracerebrally with a 10 ml aliquot
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5 cells/mL) under isofluorane anesthesia with the aid of a
stereotactic frame. After two weeks, mice were separated into three
groups in each cell line. The first, second and third groups served
as the control, MU-sh-treated (150 mg), and MC-sh-treated
(150 mg) groups respectively. MU-sh and MC-sh plasmid DNAs
were injected into the brains of nude mice using Alzet mini pumps
at the rate of 0.2 mL/h. The concentration of the plasmid solution
was 2 mg/mL (100 ml per mouse, six mice in each group). After five
weeks, the mice were sacrificed by intracardiac perfusion, first with
PBS and then with 4% paraformaldehyde in normal saline. The
brains were removed, stored in 4% paraformaldehyde, processed,
embedded in paraffin, and sectioned (5 mm thick) using a
microtome. Paraffin embedded sections were stained with
hematoxylin and eosin to visualize tumor cells and to examine
tumor volume.
Densitometry
Densitometry was performed using Image J Software (National
Institutes of Health) to quantify the band intensities obtained from
Western blot analysis and RT-PCR. Data represent average values
from 3 separate experiments.
Statistical analysis
Statistical comparisons were performed using Graph Pad Prism
software (version 3.02). Quantitative data from Western blot
analysis, RT-PCR, adhesion, migration and invasion assays was
evaluated for statistical significance using one-way ANOVA.
Bonferroni’s post hoc test (multiple comparison tests) was used to
compare any statistical significance between groups. Differences in
the values were considered significant at p,0.05.
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